## Impact of the 2011 off the Pacific coast of Tohoku Earthquake

**Osaka, Japan, March 15, 2011** - Shionogi would like to express condolences to the victims and sincerely hope for the recovery of the people affected by the disaster on March 11, 2011.

To ascertain the damage situation and maintain a stable supply of the prescription drugs which Shionogi group handles, Shionogi established a task force at its head office on the same day.

The earthquake has affected the operation of Shionogi as follows.

### 1. Damage situation

(1) Human suffering

There has been no report of casualties or missing person on employees in the disaster area.

(2) Facility situation

Shionogi has decided to suspend all operation in Kanegasaki Plant (Kanegasaki-cho, Isawa-gun, Iwate) because of the damage to a part of buildings and facilities, and also because of the risk of electricity blackouts and aftershock. The Company is putting all its effort into the action for restoration. The concrete schedule for when the operation may resume have yet to be determined.

#### 2. Impact on business performance

The damage situation and the impact on business performance as a result of the earthquake are currently underway. Shionogi will make an announcement in case a significant impact to Shionogi group is expected.

#### **Forward-Looking Statements**

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

# For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596